The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.
Merck (MRK) announced plans to separate its core pharmaceutical division into two units as it prepares for the upcoming ...
The drugmaker is reorganizing to bolster product launches ahead its cancer drug Keytruda’s patent loss.
Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...
The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...
LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...
FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in ...
A vaccine combined with Keytruda is associated with a 49% reduction in the risk of recurrence or death. Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results